Casey Chisum
Family · Willis, TXNPI 1972199396
Payments from drug & device makers
Across 200 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceuticals, Inc.$1K
- Lilly USA, LLC$702
- Novo Nordisk$473
- Dexcom, Inc.$289
- Boehringer Ingelheim$278
- AstraZeneca$266
- plus $1K from 19 others
What the payments were for
- Consulting fees$1,20026%
- Food & beverage$3,50074%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biohaven Pharmaceuticals, Inc. | 2 | $1,224 |
| Lilly USA, LLC | 46 | $702 |
| Novo Nordisk | 26 | $473 |
| Dexcom, Inc. | 15 | $289 |
| Boehringer Ingelheim | 15 | $278 |
| AstraZeneca | 16 | $266 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $174 |
| Exact Sciences | 9 | $166 |
| Bayer | 8 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $145 |
| Amgen(2 entities) | 7 | $120 |
| GSK | 6 | $119 |
| AbbVie | 6 | $109 |
| Pfizer | 5 | $108 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $89 |
| Astellas Pharma US Inc | 3 | $68 |
| Tolmar, Inc. | 2 | $35 |
| Antares Pharma, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Medtronic | 1 | $24 |
| Merck | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Vivus LLC | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$1,200
How this compares
$4,700 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 60 | $97,486 |
| MounjaroTirzepatide | 52 | $96,669 |
| JardianceEmpagliflozin | 25 | $25,393 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $20,984 |
| EliquisApixaban | 12 | $13,518 |
| Levothyroxine Sodium | 144 | $1,742 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $1,534 |
| Levocetirizine Dihydrochloride | 71 | $1,226 |
| Atorvastatin Calcium | 79 | $1,122 |
| Gabapentin | 71 | $994 |
| Liothyronine Sodium | 27 | $976 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 110 | $873 |
| Bupropion XlBupropion Hcl | 28 | $845 |
| Rosuvastatin Calcium | 87 | $825 |
| Famotidine | 66 | $754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $473 | $97,48660 claims |
| Lilly USA, LLCMounjaro | $702 | $96,66952 claims |
| Boehringer IngelheimJardiance | $278 | $25,39325 claims |
| GSKTrelegy Ellipta | $119 | $20,98427 claims |
| PfizerEliquis | $108 | $13,51812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Willis
- Tara DraehnWillis$35K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.